MondayNightIBD ~ Treat-to-Target Clinical Convo
October 21, 2024 ~ Jami Kinnucan, MD
Pre-assessment

Before you view this activity, please take this pre-assessment. Taking this pre-assessment does not immediately qualify learners to earn credit.

Certificates of credit will only be sent to learners who also receive a passing score on the post-test (separate from this survey), and fill out the evaluation form and application for credit.

Question Title

* 1. What are your specialty and credentials?

IBD Specialist

General GI

Colorectal Surgeon

Fellow/Trainee

APP

Nurse

PharmD

Other (please specify)

Question Title

* 2. What is your community of practice?

Academic

Community

Industry

Question Title

* 3. In the CALM study comparing conventional treatment vs T2T treatment escalation in bionaive Crohn's patients starting adalimumab, mucosal healing at week 48 was defined as?

(CDEIS: Crohn's Disease Endoscopic Index of Severity)

CDEIS 0 and no ulcers

CDEIS = 0 (normal exam)

CDEIS <4 and no deep ulcers

Deep ulcers< 10% of bowel surface

Question Title

* 4. 55 with recent diagnosis of colonic Crohn’s disease, SESCD 6, FCP 850, started on Vedolizumab. At 3 month FCP 100, Colonoscopy at 1yr : endo remission.

According to the AGA 2023 guidelines, how can you periodically (every few months) rule out active inflammation moving forward?

Clincial symtoms check

FCP check <150

Endoscopy

CT or MRI

Question Title

* 5. Completing this pre-survey does not qualify you for a CME certificate. Only after completing the post-survey & evaluation form will a certificate be issued.

First & Last Name, Credentials

🔗 Proceed to activity on X/MondayNightIBD

🔗 Proceed to post-survey (post-survey completion must occur on or after activity launch date to be valid for claiming credit)

MondayNightIBD ~ Treat-to-Target Clinical ConvoOctober 21, 2024 ~ Jami Kinnucan, MD **Pre-assessment**

Question Title

* 1. What are your specialty and credentials?

Question Title

* 2. What is your community of practice?

Question Title

* 3. In the CALM study comparing conventional treatment vs T2T treatment escalation in bionaive Crohn's patients starting adalimumab, mucosal healing at week 48 was defined as? (CDEIS: Crohn's Disease Endoscopic Index of Severity)

Question Title

* 4. 55 with recent diagnosis of colonic Crohn’s disease, SESCD 6, FCP 850, started on Vedolizumab. At 3 month FCP 100, Colonoscopy at 1yr : endo remission. According to the AGA 2023 guidelines, how can you periodically (every few months) rule out active inflammation moving forward?

Question Title

* 5. Completing this pre-survey does not qualify you for a CME certificate. Only after completing the post-survey & evaluation form will a certificate be issued.

MondayNightIBD ~ Treat-to-Target Clinical Convo
October 21, 2024 ~ Jami Kinnucan, MD
Pre-assessment

* 3. In the CALM study comparing conventional treatment vs T2T treatment escalation in bionaive Crohn's patients starting adalimumab, mucosal healing at week 48 was defined as?

(CDEIS: Crohn's Disease Endoscopic Index of Severity)

* 4. 55 with recent diagnosis of colonic Crohn’s disease, SESCD 6, FCP 850, started on Vedolizumab. At 3 month FCP 100, Colonoscopy at 1yr : endo remission.

According to the AGA 2023 guidelines, how can you periodically (every few months) rule out active inflammation moving forward?